PharmaPendium®
2018.16 Release

The content release includes the following updates:

1. **6 New Drugs in PharmaPendium**
   - Binimetinib
   - Elagolix Sodium
   - Encorafenib
   - Ivosidenib
   - Rucaparib Camsylate
   - Tecovirimat

2. **FDA Approval Documents**
   - 273 new FDA Approval Documents
   - 6,159 new pages of FDA Approval Documents

3. **The new totals for PharmaPendium are:**
   - 2,494,324 pages of FDA Approval documents (Including FDA Classic Collection)
   - 114,036 documents of FDA Approval documents (Including FDA Classic Collection)
   - 4,541 drugs with data in PharmaPendium
   - 1,796,635 extracted safety data lines
   - 1,689,908 extracted PK data lines
   - 332,477 extracted ME data lines
   - 2,865,250 extracted Efficacy data lines
   - 128,749 extracted Activity data lines
   - 11,447,776 FAERS (post-marketing) reports
   - 12,879 documents / 235,146 pages of EMA Approval documents
   - 7,854 documents / 706,600 pages of FDA Advisory Committees Meetings documents
   - 10,906 documents / 308,149 pages of FDA Classic Collection
   - 2,769 documents / 32,290 pages of DESI documents

Copyright © 2018 Elsevier Life Sciences IP Limited. All rights reserved. PharmaPendium is a trade mark of Elsevier Life Sciences IP Limited. RELX Group and the RE symbol are trade marks of RELX Group plc, used under license.

August 2018